PDCD1 and head and neck squamous cell carcinoma: Unfortunately, additional investigation into combination nivolumab (another PD-1 inhibitor) with stereotactic body radiotherapy in R/M HNSCC has found no evidence of objective response rate improvement, which remains relatively low for PD-1 inhibitors in general in R/M HNSCC [59].